CB1 is the most abundant receptor in the human brain. Not the most abundant cannabinoid receptor — the most abundant receptor, period. More CB1 sites exist in your brain than serotonin receptors, dopamine receptors, or GABA receptors. Cannabis isn’t interacting with some niche corner of your neurology. It’s engaging the most densely distributed receptor system your brain has. The more interesting question is why that system exists, what it’s normally doing when you haven’t consumed anything, and why it responds to both your body’s own compounds and the cannabinoids in hemp.
🧪 Lab Tested | 👩💼 Woman-Owned | 🏆 Est. 2017
What a Receptor Actually Is
A receptor is a protein embedded in a cell membrane that changes its shape when a specific molecule binds to it. The shape change triggers a signaling cascade inside the cell (turning processes on or off, opening or closing ion channels, or releasing secondary messenger molecules). Receptors don’t do things themselves; they transduce chemical signals into cellular responses.
CB1 and CB2 are both G protein-coupled receptors (GPCRs), the most common receptor superfamily in the human genome. GPCRs work through intermediate proteins (G proteins) that activate downstream cellular effects when the receptor is engaged. The specific G protein type connected to CB1 and CB2 is Gi/o, which generally inhibits downstream signaling. Cannabinoid receptor activation typically produces inhibitory effects on neurons (less neurotransmitter release, less excitability, less signaling) rather than stimulatory ones.
CB1 was identified in 1988 by Allyn Howlett’s research group at Saint Louis University. CB2 was identified in 1993 by Sean Munro’s group at the MRC Laboratory of Molecular Biology in Cambridge. The discovery of these receptors immediately prompted the obvious question: why does the brain have receptors that respond to compounds from a plant? The answer, discovered shortly afterward, is that the brain makes its own compounds that use these receptors. Cannabis is borrowing a key that already has a lock.
CB1: Location, Function, and Why Signaling Runs Backwards
CB1 receptors are concentrated in the central nervous system, with the highest densities in the basal ganglia, cerebellum, hippocampus, prefrontal cortex, and cingulate cortex. Their distribution maps almost exactly onto the effects cannabis produces: movement coordination (basal ganglia, cerebellum), short-term memory (hippocampus), decision-making and executive function (prefrontal cortex), and emotional processing (cingulate cortex). The receptor geography is the pharmacological explanation for the experiential map.
Basal Ganglia
The highest CB1 receptor density in the brain. The basal ganglia coordinates motor control and habit formation. Dense CB1 expression here explains why cannabis affects movement precision and produces the characteristic motor relaxation associated with higher doses. It also contributes to the appetitive and reward aspects of the experience, as the basal ganglia is deeply connected to the dopamine reward system.
Hippocampus
CB1 receptors throughout the hippocampus modulate glutamate and GABA release (the primary excitatory and inhibitory neurotransmitters that control how memories form and consolidate). THC’s short-term memory effects trace directly to CB1 activation here. CB1 expression in the hippocampus also connects the ECS to stress response and emotional memory formation, both of which depend on hippocampal glutamate and GABA balance.
Cerebellum
CB1 in the cerebellum modulates coordination and timing of movement. High doses of THC produce cerebellar effects: altered time perception, reduced balance precision, and the characteristic slowing of motor coordination. Timing perception runs through cerebellar circuits. The changes cannabis produces in how music and rhythm feel are a cerebellar effect, not an auditory one.
Prefrontal Cortex
CB1 receptors in the prefrontal cortex modulate both glutamate and GABA signaling, affecting executive function, working memory, and decision-making. Both excitatory and inhibitory neurons in the PFC express CB1, and the balance of their modulation determines whether cannabis produces anxiety (excess glutamate disinhibition) or relaxation (sufficient GABA upregulation). CBD’s negative allosteric modulation at CB1 is particularly relevant in the PFC context.
Brain Stem
CB1 expression in the brain stem is notably sparse. This absence has significant safety implications: the brain stem controls breathing and heart rate, and the lack of CB1 receptors there is why cannabis cannot cause respiratory arrest. Opioid receptors, by contrast, are densely expressed in the brain stem. Opioid overdose causes fatal respiratory depression; cannabis cannot.
The retrograde signal: why it works backwards
Most neurotransmitter systems work in one direction. Neuron A releases a signal from its axon terminal. Neuron B receives the signal at its dendrite. Information travels forward.
The endocannabinoid system works backwards. Postsynaptic neurons (neuron B) produce endocannabinoids on demand in response to activity. Those endocannabinoids travel backwards across the synapse and bind to CB1 receptors on the presynaptic neuron (neuron A), reducing how much neurotransmitter A is about to release. The system is a feedback mechanism that lets the receiving neuron regulate how much signal it’s getting from the sending neuron. It’s an on-demand volume control, running against the standard direction of neural communication.
THC hijacks this system by flooding the same receptor sites with a more stable, longer-lasting agonist. The result is sustained suppression of neurotransmitter release across multiple synapses simultaneously. The subjective effects of cannabis are diffuse and system-wide rather than localized to a single function because the receptor targets are distributed throughout the brain.
CB2: The Immune System Receptor
CB2 receptors were long characterized as the “peripheral” receptor because their original discovery was in immune tissues outside the brain. That picture has become more complicated. CB2 is now known to be expressed in the brain as well, particularly in microglia (the brain’s immune cells), and its brain expression increases during neuroinflammatory states.
The primary CB2 distribution includes:
- Immune cells: B cells, natural killer cells, monocytes, macrophages, and T cells all express CB2. Activation suppresses pro-inflammatory cytokine release and modulates immune cell migration.
- Peripheral sensory neurons: CB2 on peripheral nociceptors (pain-sensing neurons) modulates pain signal transmission without the psychoactive effects associated with central CB1 activation.
- Gut tissue: The gastrointestinal tract expresses CB2, with activation contributing to reduced gut motility and intestinal inflammation.
- Bone tissue: Osteoclasts and osteoblasts (cells that break down and build bone) express CB2, with receptor activation linked to bone density regulation in research models.
- Microglia: Brain-resident immune cells upregulate CB2 expression during neuroinflammation, positioning CB2 as an endogenous anti-inflammatory regulator in the CNS under pathological conditions.
CB2 activation does not produce psychoactive effects. The psychoactivity of cannabis comes from CB1 activation in the brain, not CB2. Beta-caryophyllene (a terpene that directly binds CB2) and certain synthetic CB2-selective agonists can therefore produce anti-inflammatory effects without any psychoactive component.
Your Body’s Own Cannabinoids
The endocannabinoid system was named after cannabis, not the other way around. Researchers identified CB1 and CB2, reasoned that the body must make its own compounds to activate them, and then went looking. They found two primary endogenous cannabinoids.
Primary CB1 Agonist
Anandamide (AEA)
Named from the Sanskrit word for bliss. Anandamide is a full agonist at CB1 and a partial agonist at CB2. It is also an endogenous vanilloid, activating TRPV1 receptors (the same receptor activated by capsaicin in hot peppers). Anandamide is produced on demand in the postsynaptic neuron and broken down rapidly by the enzyme FAAH (fatty acid amide hydrolase). CBD inhibits FAAH, extending anandamide’s active life in the synapse. That FAAH inhibition is one documented mechanism behind CBD’s reported anxiolytic effects.
Primary CB1/CB2 Agonist
2-Arachidonoylglycerol (2-AG)
2-AG is present in the brain at concentrations roughly 170 times higher than anandamide. It is a full agonist at both CB1 and CB2. While anandamide is considered the primary endogenous CB1 ligand in tone-setting and mood regulation, 2-AG is thought to be the primary mediator of activity-dependent retrograde signaling (the on-demand feedback mechanism). It is broken down by the enzyme MAGL (monoacylglycerol lipase). Some cannabis-adjacent research focuses on MAGL inhibition as an alternative approach to endocannabinoid augmentation.
The endocannabinoid system predates cannabis by approximately 500 million years. Primitive invertebrates like sea squirts have functional CB1 homologs. The system appears to have been conserved across animal evolution because retrograde synaptic modulation (the ability of a receiving neuron to regulate what it gets from a sending neuron) is a fundamental tool of nervous system regulation, not a feature that developed for any particular purpose.
How Phytocannabinoids Interact with CB1 and CB2
Phytocannabinoids (cannabinoids from the plant) interact with the same receptors that endocannabinoids use, but with different binding affinities, different action types, and different durations.
| Cannabinoid | CB1 | CB2 | TRPV1 | 5-HT1A | FAAH | Key Behavioral Effect |
|---|---|---|---|---|---|---|
| THC (Delta-9) | Full agonist | Partial agonist | Activates | Weak | Minimal | Psychoactivity, appetite, altered time perception |
| CBD | Neg. allosteric mod. | Partial agonist | Activates/desensitizes | Activates | Inhibits | Anxiolytic, anti-CB1 (reduces THC ceiling) |
| CBG | Partial agonist | Partial agonist | Activates | Activates | Inhibits | Mild CB1 tone, mood, anti-inflammatory |
| CBN | Partial agonist | Partial agonist | Weak | Minimal | Minimal | Sedation (particularly with THC present) |
| CBC | Weak direct | Partial agonist | Activates | Weak | Minimal | Anti-inflammatory via CB2 and TRPV1 |
| Delta-8 THC | Partial agonist | Partial agonist | Weak | Weak | Minimal | Milder CB1 psychoactivity than Delta-9 |
CBD does not directly activate CB1. It’s a negative allosteric modulator, meaning it binds a different site on the receptor and changes its shape in a way that reduces how effectively THC (or anandamide) can activate it. CBD doesn’t block THC from binding. It reduces the maximum signal strength of whatever is binding. CBD products blended with THC produce a different experience than THC alone because the CB1 activation ceiling is lower, the anxiety-inducing effects are moderated, and the overall experience is more controlled.
THC binds CB1 with much higher affinity than anandamide and persists on the receptor far longer. Anandamide is broken down by FAAH within seconds to minutes of release. THC, lacking the same enzymatic target, can occupy CB1 receptors for hours. The duration of cannabis effects is a function of this persistence, not of any pharmacological strength per molecule.
Beyond CB1 and CB2
CB1 and CB2 were identified first and studied most extensively, but cannabinoids interact with several other receptor types that contribute meaningfully to their effects.
TRPV1 (Transient Receptor Potential Vanilloid 1)
TRPV1 is the receptor responsible for the heat sensation from capsaicin in hot peppers. Anandamide activates TRPV1 at high concentrations, and CBD activates and then desensitizes it (a process that may contribute to CBD’s anti-inflammatory effects by reducing the receptor’s sensitivity to ongoing pain signals). Beta-caryophyllene’s CB2 agonism and TRPV1 interactions position certain terpenes as relevant contributors to the anti-inflammatory picture alongside cannabinoids.
5-HT1A (Serotonin Receptor)
CBD and CBG both activate 5-HT1A serotonin receptors. The anxiolytic effects associated with CBD have been partly attributed to this mechanism in preclinical research. 5-HT1A activation produces calming and mood-stabilizing effects through the serotonin system, independently of any CB1 or CB2 activity. Limonene and linalool (terpenes) also activate 5-HT1A. Terpene-rich full-spectrum products therefore reach anxiolytic pathways that CBD isolate at equivalent milligram doses cannot access.
GPR55 (Orphan Receptor)
GPR55 is sometimes described as a candidate for “CB3” status, though this classification remains debated. Both THC and CBD interact with GPR55, and activation is associated with modulation of pain signaling and bone density regulation. The receptor is called an “orphan” receptor because its primary endogenous ligand has not been definitively established, though lysophosphatidylinositol has been proposed.
GABA-A
Linalool, a terpene found in lavender-forward cannabis strains, modulates GABA-A receptors (the target of benzodiazepines and alcohol). The sedative quality of linalool-rich strains operates through a different receptor pathway than CB1. The entourage effect from terpene-rich full-spectrum products includes mechanisms that CBD or THC alone cannot produce, specifically because these terpene pathways reach receptor targets the cannabinoids miss. GABA-A modulation via terpenes adds a sedating dimension that pure cannabinoid products cannot replicate.
Frequently Asked Questions
CB1 and CB2 are G protein-coupled receptors that form the primary receptor targets of the endocannabinoid system. CB1 is concentrated in the central nervous system (particularly the basal ganglia, hippocampus, cerebellum, and prefrontal cortex) and mediates the psychoactive effects of THC. CB2 is distributed primarily in immune tissue and peripheral sensory neurons, where it modulates inflammation and pain signaling without producing psychoactive effects. Both receptors are activated by the body’s own endocannabinoids (anandamide and 2-AG) as well as by phytocannabinoids from cannabis.
CB1 acts as a retrograde regulator of neurotransmitter release. Postsynaptic neurons produce endocannabinoids on demand that travel backwards across the synapse and bind CB1 on the presynaptic neuron, reducing how much neurotransmitter the presynaptic neuron releases. The system functions as a volume control on neural activity. The receiving neuron can turn down the signal it’s getting from the sending neuron. CB1 modulates glutamate, GABA, dopamine, and serotonin release across the brain depending on the synapse type.
CB1 is concentrated in the brain and central nervous system, mediating psychoactive effects, motor function, memory, and appetite. CB2 is distributed primarily in immune tissue and the periphery, where it modulates inflammation, pain signal transmission, and immune cell activity. CB1 activation by THC produces psychoactivity. CB2 activation does not. Some terpenes like beta-caryophyllene directly activate CB2, adding an anti-inflammatory layer to full-spectrum products without contributing to psychoactive effects.
CBD interacts with both receptors but not as a direct agonist at CB1. At CB1, CBD acts as a negative allosteric modulator. It binds a different site on the receptor and reduces how effectively THC or anandamide can activate it, without blocking their binding. At CB2, CBD acts as a partial agonist, directly contributing to CB2’s anti-inflammatory activity. CBD also inhibits FAAH (the enzyme that breaks down anandamide), which raises circulating anandamide levels and indirectly increases natural CB1 tone.
Endocannabinoids are cannabinoid-like compounds the body produces itself to activate CB1 and CB2 receptors. The two primary ones are anandamide (AEA), a full CB1 agonist that also activates TRPV1, and 2-arachidonoylglycerol (2-AG), a full CB1 and CB2 agonist present in the brain at much higher concentrations than anandamide. Both are produced on demand in postsynaptic neurons and broken down enzymatically (anandamide by FAAH, 2-AG by MAGL) rather than being stored and released like conventional neurotransmitters.
CB1 is a core component of a retrograde feedback system that allows neurons throughout the brain to regulate how much excitatory and inhibitory signaling they receive. Because this feedback mechanism is relevant to nearly every brain circuit, CB1 is expressed across most brain regions. That breadth of distribution is what makes it the most abundant receptor in the brain. Its abundance is not a curiosity but a function of how broadly useful the on-demand retrograde signal is to neural regulation.
CB1 receptors are notably absent from the brain stem, which controls respiratory rate and heart rate. The brain stem densely expresses opioid receptors, which is why opioid overdose causes fatal respiratory depression. Cannabis, activating CB1, cannot suppress breathing because the relevant control center lacks the receptor. This anatomical distribution is not an accident. The endocannabinoid system’s role in retrograde synaptic modulation in the cortex, hippocampus, and basal ganglia doesn’t require brain stem expression.
Yes. CBG is a partial agonist at both CB1 and CB2, and also inhibits FAAH and activates 5-HT1A. CBN is a partial agonist at CB1 and CB2, with its sedative effects most pronounced in combination with THC rather than alone. CBC activates CB2 and TRPV1 but has weak direct CB1 activity. Delta-8 THC is a partial agonist at CB1 producing milder psychoactivity than Delta-9. Terpenes like beta-caryophyllene directly activate CB2, adding to the receptor interaction profile of full-spectrum products beyond the cannabinoids alone.
Full-Spectrum Means All of This Is Working at Once. COA on Every Batch.
Third-party tested. ISO-accredited lab. Woman-owned since 2017.